ZD 198615
Latest Information Update: 21 Jan 2008
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Leukotriene receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed
- 04 Mar 1997 No-Development-Reported for Asthma in United Kingdom (Unknown route)